Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

The phase 3 AURIGA study evaluated daratumumab (Darzalex) and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who were in very good partial response, minimal ...

Panelists discuss how the IMROZ trial demonstrated improved outcomes with quadruplet therapy combining daratumumab, lenalidomide, melphalan, and prednisone in patients with transplant-ineligible newly ...

GSK continues to build the case for its multiple myeloma therapy Blenrep ... Johnson’s $10 billion-a-year anti-CD38 antibody Darzalex (daratumumab) with PomDex in the head-to-head DREAMM ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

Previously we used to use Anti-CD38 ... myeloma also include the use of PCMA based therapy. BCMA is B-cell maturation antigen and it is a way for us to target the myeloma cell. So there are ...

It joins a number of other BCMA-directed therapies for multiple myeloma ... generated anti-CD38 blockbuster Darzalex (daratumumab). Talquetamab has also shown promise in myeloma in the phase ...

are bispecific antibodies that activate T cells by targeting CD3 and that have been approved for the treatment of triple-class–exposed relapsed or refractory multiple myeloma. A total of 94 ...

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...